Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients

Peter Weiss, Carlos A. Dujovne, Simeon Margolis, Louis Lasagna, Joseph R. Bianchine

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The ability of a tetralin phenoxy isobutyrate, SU-13437, to lower serum lipids was compared with that of a matching placebo in a double-blind crossover study. Treatment with SU-13437 for 4 weeks lowered serum cholesterol by 23 per cent in hypercholesterolemic patients, and it lowered serum triglycerides by 68 per cent in hypertriglyceridemic patients. None of the patients failed to respond to treatment. Gastrointestinal upset was seen in 2 of the 29 patients, and one patient had transient elevation of serum glutamic oxaloacetic transaminase.

Original languageEnglish (US)
Pages (from-to)90-96
Number of pages7
JournalClinical Pharmacology & Therapeutics
Issue number1
StatePublished - 1970
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients'. Together they form a unique fingerprint.

Cite this